What Is a Soft Tissue Mass? Types, Causes & Diagnosis

A soft tissue mass is any lump or growth that develops in the body’s connective tissues, which include fat, muscle, tendons, nerves, blood vessels, and the tissue surrounding joints. Most soft tissue masses turn out to be benign, and many are not even true tumors but rather reactive or inflammatory conditions that produce a noticeable lump. Still, because soft tissue sarcomas (the malignant versions) do exist and can be serious, any new or growing mass in these tissues deserves a careful look.

What Counts as Soft Tissue

The term “soft tissue” covers everything that is not bone, cartilage, or the internal lining of organs. Under the World Health Organization convention, soft tissue includes connective, subcutaneous, and other non-organ tissues, as well as the peripheral and autonomic nervous system.¹ That gives soft tissue masses an enormous range of possible locations and compositions. A lump in the fatty layer just beneath your skin, a growth deep within a thigh muscle, a swollen nerve sheath in the forearm, or a vascular tangle in the calf can all fall under the same umbrella.

Because soft tissue is distributed throughout the entire body, these masses can appear almost anywhere. They show up most often in the extremities, particularly the thigh and shoulder areas, but also crop up in the trunk, the retroperitoneum (the space behind the abdominal cavity), and the head and neck region. Location alone does not tell you whether a mass is harmless or worrisome, but it does influence which imaging tools work best and what the range of possible diagnoses looks like.

Benign Soft Tissue Tumors

The vast majority of soft tissue masses that lead someone to a doctor’s office are benign. Lipomas, which are slow-growing lumps made of mature fat cells, are the single most common type of soft tissue tumor.² Most lipomas sit just under the skin, feel soft and rubbery, and move slightly when you press on them. They are usually painless and rarely grow larger than a few centimeters. Lipomas that develop deeper, underneath the tough fascia layer or even inside a muscle, are less common but can be harder to diagnose because their imaging appearance sometimes overlaps with that of well-differentiated liposarcomas, a low-grade malignancy.²

Beyond lipomas, other common benign growths include:

Fibromas: firm lumps composed of fibrous connective tissue, often found in tendons or ligaments.
Hemangiomas: tangles of blood vessels that can appear anywhere from just beneath the skin to deep within muscle. They are particularly common in children.
Schwannomas and neurofibromas: growths arising from the sheath of peripheral nerves. These sometimes cause tingling or pain along the nerve’s path.
Myxomas: gelatinous-feeling masses that tend to arise in large muscles, especially in the thigh.

Most benign soft tissue tumors grow slowly, remain small, and cause symptoms only if they press on a nerve or sit in an inconvenient spot. Many people live with a small lipoma for years without needing treatment.

Masses That Are Not Tumors at All

Not every soft tissue mass is a neoplasm, meaning a true new growth of cells. A surprisingly large share of lumps referred to specialists turn out to be non-neoplastic conditions that simply look like tumors on initial examination. Ganglion cysts (fluid-filled sacs near joints or tendons), abscesses, hematomas from old injuries, bursitis, and foreign body reactions can all present as a palpable lump that raises alarm.³

One particularly tricky mimic is myositis ossificans, a condition in which bone-like tissue forms inside soft tissue, usually after a significant blow or muscle injury. In its early stages, it can look aggressive on imaging and fool clinicians into thinking it might be a sarcoma. As it matures, a characteristic rim of calcification develops on X-ray that gives the diagnosis away, but before that rim appears, unnecessary biopsies and even surgeries have been performed on what turns out to be a self-limiting process.⁴ Radiographs can help by revealing features like an ossific rim, periosteal reaction from a fibro-osseous pseudotumor, or a retained foreign body causing a reaction.⁵

In a review of pediatric soft tissue masses referred to a tertiary sarcoma center, roughly six in ten cases turned out to be non-neoplastic, about a third were benign tumors, and only around 5% were malignant.⁶ That ratio is skewed because these were referrals to a specialist center where suspicion was already raised, and yet malignancy was still uncommon. In the general population, the odds of a random soft tissue lump being cancerous are even lower.

Malignant Soft Tissue Tumors

Soft tissue sarcomas are the malignant counterparts, and they are rare. They account for less than 1% of all adult cancers. Within that small group, there is enormous variety. More than 50 recognized subtypes exist, but five of them make up about three-quarters of cases: undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor.⁷ Other significant subtypes include myxofibrosarcoma, angiosarcoma, epithelioid sarcoma, and radiation-induced sarcoma.⁸

Getting the subtype right matters enormously for treatment. At the molecular level, sarcomas fall into two broad camps. Some carry specific, identifiable genetic changes, like a gene fusion or a characteristic mutation, that essentially define the tumor. Ewing sarcoma, for instance, carries a specific fusion gene, while gastrointestinal stromal tumors carry KIT or PDGFRA mutations that can be targeted with drugs. The other camp includes sarcomas with complex, chaotic chromosomal rearrangements and no single defining alteration, such as leiomyosarcoma and pleomorphic liposarcoma.⁹ This molecular distinction is not just an academic exercise; it determines whether a targeted therapy might work and helps pathologists confirm a diagnosis when the tissue looks ambiguous under a microscope.

Causes and Risk Factors

For benign masses like lipomas, the cause is usually unknown. They tend to run in families, and people sometimes develop several at once, but no clear environmental trigger has been established. For sarcomas, most cases arise without an obvious cause, which is part of what makes them frustrating to study and prevent.

That said, several known risk factors raise the likelihood of developing a soft tissue sarcoma. Environmental exposures, particularly prior radiation therapy and certain chemical carcinogens, are well-established contributors.¹⁰ Radiation-induced sarcoma typically develops years or even decades after radiation treatment for an earlier cancer, appearing in or near the radiation field.

Genetic predisposition also plays a role. Several inherited cancer syndromes carry a meaningful risk of sarcoma. Li-Fraumeni syndrome, caused by mutations in the TP53 tumor suppressor gene, is the best-known example.¹⁰ A variety of other sarcomas develop in the context of heritable cancer predisposition syndromes, associations that are often overlooked given how rare both sarcomas and these syndromes are individually.¹¹ Recent estimates suggest that up to about one in five sarcomas may be linked to alterations in cancer predisposition genes, a higher proportion than many clinicians previously assumed.¹²

When Should You Worry About a Lump

Most soft tissue lumps are painless, superficial, and small, which describes the typical benign lipoma. Still, certain features should prompt you to see a doctor sooner rather than later. Japanese clinical guidelines note that malignant soft tissue tumors tend to be larger than 5 cm, tend to sit in deep tissue layers rather than just under the skin, and tend to grow quickly, though there are many exceptions to all three of these rules.¹³ Ultrasound data support the same pattern: a mass larger than 5 cm with irregular, infiltrated margins is highly suggestive of malignancy.¹⁴

Pain is not a reliable indicator either way. Some benign nerve sheath tumors are exquisitely painful, while some sarcomas grow to a large size without causing any discomfort. A mass that is new, growing, deep-seated, firm, or fixed in place (meaning it does not slide around under the skin) warrants further evaluation even if it does not hurt.

How Soft Tissue Masses Are Diagnosed

Diagnosis usually begins with imaging. The specific modality depends on the mass’s size, location, and how suspicious it looks on initial examination.

Ultrasound

Ultrasound is typically the first stop for a mass you can feel near the surface. It is quick, widely available, involves no radiation, and does a good job of determining whether a lump is a simple fluid-filled cyst or a solid mass. With Doppler imaging, it can also show blood flow within the mass, which helps characterize vascularity.¹⁵ For clearly benign-looking lesions like a classic superficial lipoma, ultrasound alone may be enough to close the case. When findings are ambiguous, ultrasound serves as the gatekeeper that decides whether the patient needs more advanced imaging.

MRI

MRI is the workhorse for evaluating soft tissue masses. It provides far better contrast between different tissue types than any other modality, making it the technique of choice for most soft tissue masses.¹⁶ In a large prospective study of 548 patients, MRI distinguished benign from malignant masses with a sensitivity of 93% and a specificity of 82%. The study also found a high negative predictive value of 98%, meaning that when MRI suggested a mass was benign, it was right 98% of the time.¹⁷ Pinning down the exact type of a malignant tumor by MRI alone, however, was much harder. A correct specific diagnosis compared with the final pathology result was achieved in about half of confirmed cases.¹⁷ MRI tells you whether something needs a biopsy with high confidence, but it cannot always tell you exactly what the tumor is.

CT

CT scans are not the primary tool for most soft tissue masses, but they fill important gaps. CT is better than MRI at detecting calcification patterns, measuring tissue density, and showing how a mass interacts with adjacent bone. These CT-specific characteristics can sometimes suggest a diagnosis that MRI alone would miss.¹⁶ CT is also preferred for masses in the chest, abdomen, or pelvis, where MRI may be less practical, and for staging purposes to check whether a sarcoma has spread to the lungs.

Biopsy and Pathology

When imaging cannot settle the question, tissue sampling is the next step. A biopsy is the only way to definitively determine what a mass is made of and whether it is malignant. Two main approaches exist for solid soft tissue masses: core needle biopsy, which uses a hollow needle to extract a small cylinder of tissue, and incisional biopsy, a minor surgical procedure that removes a wedge of the mass.

Core needle biopsy has become the preferred method for most situations. A large meta-analysis found that it correctly identified whether a mass was benign or malignant with a sensitivity of 97% and correctly classified the specific sarcoma subtype with a sensitivity of 88%.¹⁸ Compared with incisional biopsy, core needle biopsy carried a significantly lower risk of complications.¹⁸ In a study of clinic-based core needle biopsies, the correct nature of the mass was identified in about 94% of patients, with only minor complications like small hematomas.¹⁹ Another advantage: patients who underwent core needle biopsy reached their multidisciplinary tumor board discussion faster, averaging about 8 days from consultation compared with roughly 16 days for the incisional biopsy group.²⁰

Once tissue is obtained, a pathologist examines it under a microscope. For straightforward cases, the appearance of the cells is enough to make the call. For more ambiguous cases, molecular testing has become increasingly important. Many soft tissue tumors carry characteristic gene fusions or mutations, and identifying them can clinch a diagnosis that microscopy alone cannot. Some newer tumor types, like CIC-rearranged sarcoma, explicitly require molecular testing to be diagnosed.²¹ These molecular tools have also proven useful for guiding treatment decisions: knowing the specific genetic event driving a sarcoma can indicate whether a targeted therapy exists.²²

Why Specialized Centers Matter

Soft tissue sarcomas are rare enough that many general hospitals see only a handful of cases per year. That rarity creates a real problem, because getting the subtype and grade right on a biopsy requires pathologists who regularly see these tumors. A misread biopsy can lead to the wrong treatment plan or, worse, premature surgery that compromises future options. The prospective MRI study mentioned earlier noted the need for a centralized approach to soft tissue tumor pathology, precisely because outcomes improve when expertise is concentrated.¹⁷

If your doctor suspects a soft tissue sarcoma rather than a straightforward benign mass, ask about referral to a sarcoma center or at least to a musculoskeletal oncology specialist before any biopsy is performed. Even the biopsy needle track matters: surgeons plan the track so it can be removed during the eventual excision, and poorly placed biopsies can complicate later surgery.

Grading and Staging for Sarcomas

When a soft tissue mass turns out to be a sarcoma, grading and staging determine how aggressively it needs to be treated. Grading describes how abnormal the tumor cells look under a microscope and how quickly they seem to be dividing. The most widely used system assigns a grade of 1 (low), 2 (intermediate), or 3 (high) based on factors like how closely the tumor cells resemble normal tissue, how many dividing cells are visible, and how much of the tumor has died off internally. Two main grading systems are used widely, and a pediatric adaptation of one of them exists for childhood sarcomas.²³

Staging adds information about the tumor’s size and whether it has spread to lymph nodes or distant organs. Higher-grade, larger tumors with metastatic spread carry a worse prognosis, as you would expect, but even within the same stage and grade, different subtypes of sarcoma can behave very differently. A low-grade myxoid liposarcoma and a low-grade leiomyosarcoma may share a grade but follow quite different clinical paths. This is one more reason why accurate subtyping, including molecular testing when needed, is so important.

Soft Tissue Masses in Children

Soft tissue lumps in children understandably cause parental anxiety, but the odds strongly favor a benign or non-tumorous explanation. In a review of pediatric soft tissue masses referred to a tertiary sarcoma center, about 58% were non-neoplastic, around 34% were benign tumors, and only about 5% were malignant.⁶ Among children, vascular lesions like hemangiomas and vascular malformations are especially common. These tend to have distinctive imaging features that help avoid unnecessary biopsy.

The spectrum of malignant soft tissue tumors in children also differs from adults. Rhabdomyosarcoma, which arises from skeletal muscle precursor cells, is the most common childhood soft tissue sarcoma but is quite rare in adults. Conversely, the subtypes that dominate in adults, like undifferentiated pleomorphic sarcoma and leiomyosarcoma, are unusual in pediatric patients. These differences mean that a pediatric soft tissue mass needs to be evaluated with a different set of diagnostic possibilities in mind.

Surveillance After Treatment

For people who have been treated for a soft tissue sarcoma, follow-up is a long-term commitment. Sarcomas can recur locally at the original site or metastasize to distant locations, most commonly the lungs. Surveillance strategies are tailored to the individual’s risk of recurrence, which depends on the tumor’s original grade, size, depth, and subtype.²⁴ The rationale is straightforward: catching a recurrence early, when it is smaller and still resectable, offers better outcomes than discovering it after symptoms develop.

Advanced imaging plays a role in this surveillance. Guidelines generally recommend periodic MRI of the original tumor site and chest imaging (often CT) to screen for lung metastases.²⁵ The frequency of these scans typically starts high, every three to four months in the first two years when recurrence risk peaks, and gradually tapers off over five to ten years. For low-grade tumors, the schedule is less intensive. Patients sometimes worry that each follow-up scan will deliver bad news, and scan-related anxiety is well documented, but the evidence supports the practice: earlier detection of less-advanced recurrent disease can prolong survival.²⁴

1
PubMed Central. Update of pediatric soft tissue tumors with review of conventional MRI appearance-part 2
2
PubMed Central. Intramuscular lipoma: a review of the literature
3
PubMed Central. Non Lipomatous Benign Lesions Mimicking Soft-tissue Sarcomas: A Pictorial Essay
4
PubMed Central. Revisiting Myositis Ossificans: A Comprehensive Stage-by-Stage Imaging Review
5
Magnetic Resonance Imaging Clinics of North America. MR IMAGING OF SOFT-TISSUE MASSES: Mass-like Lesions that Simulate Neoplasms
6
PubMed Central. A review of paediatric soft tissues masses referred to a tertiary musculoskeletal sarcoma centre
7
PubMed. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors
8
PubMed. Overview of malignant soft-tissue sarcomas of the limbs
9
PubMed Central. Molecular classification of soft tissue sarcomas and its clinical applications
10
PubMed. Etiologic, environmental and inherited risk factors in sarcomas
11
PubMed Central. Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review
12
PubMed Central. Genetic predisposition in sarcomas: clinical implications and management
13
PubMed. Points to notice during the diagnosis of soft tissue tumors according to the Clinical Practice Guideline on the Diagnosis and Treatment of Soft Tissue Tumors
14
PubMed. Differentiation of benign and malignant superficial soft-tissue masses using grayscale and color doppler ultrasonography
15
PubMed Central. Ultrasound and Doppler US in Evaluation of Superficial Soft-tissue Lesions
16
Europe PMC. Soft-tissue masses and masslike conditions: what does CT add to diagnosis and management?
17
PubMed. Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients
18
PubMed. Core needle biopsy versus incisional biopsy for differentiation of soft-tissue sarcomas: A systematic review and meta-analysis
19
PubMed Central. Safety and Accuracy of Core Needle Biopsy for Soft Tissue Masses in an Ambulatory Setting
20
Scientific Reports. Accuracy of core needle biopsy for histologic diagnosis of soft tissue sarcoma
21
PubMed Central. Molecular testing of soft tissue tumors
22
PubMed. The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors
23
PubMed Central. Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents
24
PubMed Central. Follow-up in soft tissue sarcomas
25
PubMed Central. Does Advanced Imaging Have a Role in Detecting Local Recurrence of Soft-tissue Sarcoma?